Here we present an update of this publication, including the most recent CVOTs on GLP-1 RAs, SGLT-2 inhibitors, Insulin degludec and acarbose and discuss their implications for the medication of type 2 diabetes mellitus (T2DM) patients. The gene discussed is INS; the disease is type 2 diabetes mellitus.